Navigation Links
Interleukin Genetics, Inc. Announces Conference Call to Discuss Third Quarter 2011 Results
Date:11/3/2011

WALTHAM, Mass., Nov. 3, 2011 /PRNewswire/ -- Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and Webcast on Thursday, November 10 at 4:30 p.m. (EST) to discuss the Company's third quarter results.

To access the live call, dial 877-324-1976 (domestic) or 631-291-4550 (international). The live Webcast and replay access of the teleconference will be available on the Investors section of Interleukin Genetics, Inc.'s Website at http://www.ilgenetics.com.

About Interleukin Genetics Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics' flagship products include its proprietary PST® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA).  For more information, please visit www.ilgenetics.com.Contacts:Media:

Investors:Jon Siegal / Kirsten Fallon

Eliot LurierSchwartz MSL

Interleukin Genetics, Inc.781-684-0770

781-398-0700, ext. 1204interleukin@schwartzmsl.com

elurier@ilgenetics.com
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Interleukin Genetics, Inc. to Present at the 2011 Wedbush Securities Life Sciences Management Access Conference
2. Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2011 Results
3. Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
4. Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results
5. Interleukin Genetics, Inc. to Present at Biotech Showcase 2011
6. Interleukin Genetics, Inc. Receives Delisting Notification from NYSE Amex
7. Interleukin Genetics to Present at Upcoming Biotech Industry Meetings
8. Interleukin Genetics to Present at the 12th Annual BIO CEO Conference
9. Continued Uptake of TNF-Alpha Inhibitors and Interleukin Inhibitors Will Drive $2.2 Billion Growth in the Psoriasis Drug Market
10. Interleukin Genetics Reports Second Quarter 2009 Financial Results
11. Interleukin Genetics Announces Conference Call To Discuss Second Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and ... clinical trial team. , Using the CONSULT module, patients and physicians can schedule a ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology:
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
Breaking Biology News(10 mins):